LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 555

Search options

  1. Article ; Online: Lifestyle-Based Obesity Care.

    Ryan, Donna H

    Gastroenterology clinics of North America

    2023  Volume 52, Issue 4, Page(s) 645–660

    Abstract: Lifestyle intervention is an alluring concept. Changing behaviors to reduce food intake and increase energy expenditure will reduce body weight and body fat. Large randomized clinical trials in academic settings demonstrate lifestyle intervention can ... ...

    Abstract Lifestyle intervention is an alluring concept. Changing behaviors to reduce food intake and increase energy expenditure will reduce body weight and body fat. Large randomized clinical trials in academic settings demonstrate lifestyle intervention can produce weight loss and significant health benefits. However, they also demonstrate the problems-not all participants are able to lose even 5%, and weight regain is common. Studies conducted in real-world settings achieve modest weight loss, but no reimbursement model supports it. Health care providers need to understand the benefits and limitations of lifestyle intervention delivery in the medical office setting.
    MeSH term(s) Humans ; Exercise ; Life Style ; Obesity/therapy ; Weight Loss ; Risk Reduction Behavior ; Exercise Therapy ; Healthy Lifestyle
    Language English
    Publishing date 2023-09-14
    Publishing country United States
    Document type Journal Article ; Review ; Research Support, N.I.H., Extramural
    ZDB-ID 92114-2
    ISSN 1558-1942 ; 0889-8553
    ISSN (online) 1558-1942
    ISSN 0889-8553
    DOI 10.1016/j.gtc.2023.08.001
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Se 123: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Semaglutide and Cardiovascular Outcomes. Reply.

    Lincoff, A Michael / Ryan, Donna H / Esbjerg, Sille

    The New England journal of medicine

    2024  Volume 390, Issue 8, Page(s) 768–769

    MeSH term(s) Humans ; Glucagon-Like Peptides/therapeutic use ; Diabetes Mellitus, Type 2/drug therapy ; Obesity
    Chemical Substances semaglutide (53AXN4NNHX) ; Glucagon-Like Peptides (62340-29-8)
    Language English
    Publishing date 2024-02-21
    Publishing country United States
    Document type Letter ; Comment
    ZDB-ID 207154-x
    ISSN 1533-4406 ; 0028-4793
    ISSN (online) 1533-4406
    ISSN 0028-4793
    DOI 10.1056/NEJMc2400414
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ua VI Zs.34: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: The SELECT trial of semaglutide in patients with overweight or obesity without diabetes: establishing a new pathway to secondary prevention of cardiovascular disease.

    Lincoff, A Michael / Ryan, Donna H

    European heart journal. Cardiovascular pharmacotherapy

    2023  Volume 10, Issue 2, Page(s) 93–94

    MeSH term(s) Humans ; Cardiovascular Diseases/prevention & control ; Diabetes Mellitus ; Glucagon-Like Peptides/therapeutic use ; Obesity/drug therapy ; Overweight/drug therapy ; Secondary Prevention ; Clinical Trials as Topic
    Chemical Substances Glucagon-Like Peptides (62340-29-8) ; semaglutide (53AXN4NNHX)
    Language English
    Publishing date 2023-12-09
    Publishing country England
    Document type Journal Article
    ZDB-ID 2808613-2
    ISSN 2055-6845 ; 2055-6837
    ISSN (online) 2055-6845
    ISSN 2055-6837
    DOI 10.1093/ehjcvp/pvad097
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Semaglutide for obesity: four STEPs forward, but more to come.

    Ryan, Donna H

    The lancet. Diabetes & endocrinology

    2021  Volume 9, Issue 5, Page(s) 252–254

    MeSH term(s) Animals ; Clinical Trials, Phase III as Topic/methods ; Energy Metabolism/drug effects ; Energy Metabolism/physiology ; Glucagon-Like Peptide-1 Receptor/agonists ; Glucagon-Like Peptide-1 Receptor/metabolism ; Glucagon-Like Peptides/pharmacology ; Glucagon-Like Peptides/therapeutic use ; Humans ; Hypoglycemic Agents/pharmacology ; Hypoglycemic Agents/therapeutic use ; Obesity/drug therapy ; Obesity/metabolism
    Chemical Substances Glucagon-Like Peptide-1 Receptor ; Hypoglycemic Agents ; semaglutide (53AXN4NNHX) ; Glucagon-Like Peptides (62340-29-8)
    Language English
    Publishing date 2021-04-14
    Publishing country England
    Document type Journal Article ; Review
    ISSN 2213-8595
    ISSN (online) 2213-8595
    DOI 10.1016/S2213-8587(21)00081-4
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  5. Article ; Online: Next Generation Antiobesity Medications: Setmelanotide, Semaglutide, Tirzepatide and Bimagrumab: What do They Mean for Clinical Practice?

    Ryan, Donna H

    Journal of obesity & metabolic syndrome

    2021  Volume 30, Issue 3, Page(s) 196–208

    Abstract: There is a new generation of antiobesity drugs in development or just arriving on the scene. First, setmelanotide has been approved for three of the ultrarare genetic conditions that cause obesity-pro-opiomelanocortin deficiency, proprotein convertase ... ...

    Abstract There is a new generation of antiobesity drugs in development or just arriving on the scene. First, setmelanotide has been approved for three of the ultrarare genetic conditions that cause obesity-pro-opiomelanocortin deficiency, proprotein convertase subtilisin and kexin type 1 (an important enzyme in the melanocortin pathway) and leptin receptor deficiency. Setmelanotide marks the first in a personalized medicine approach to obesity. Second, semaglutide 2.4 mg once weekly has been submitted to regulators in the United States and the European Union for approval for patients with obesity (body mass index [BMI] ≥30 kg/m
    Language English
    Publishing date 2021-09-13
    Publishing country Korea (South)
    Document type Journal Article ; Review
    ZDB-ID 3021984-X
    ISSN 2508-7576 ; 2508-6235
    ISSN (online) 2508-7576
    ISSN 2508-6235
    DOI 10.7570/jomes21033
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article: Drugs for Treating Obesity.

    Ryan, Donna H

    Handbook of experimental pharmacology

    2021  Volume 274, Page(s) 387–414

    Abstract: Older medications approved for chronic weight management (orlistat, naltrexone/bupropion, liraglutide 3 mg and, in the USA, phentermine/topiramate) have not been widely adopted by health care providers. Those medications produce only modest additional ... ...

    Abstract Older medications approved for chronic weight management (orlistat, naltrexone/bupropion, liraglutide 3 mg and, in the USA, phentermine/topiramate) have not been widely adopted by health care providers. Those medications produce only modest additional weight loss when used to augment lifestyle intervention. However, semaglutide 2.4 mg weekly has recently emerged and produces much more weight loss - on average 15% weight loss at 1 year. Semaglutide's enhanced efficacy and that its class (GLP-1 receptor analogs) is well-known may result in more clinicians adopting pharmacotherapy. Furthermore, the first dedicated cardiovascular outcome trial powered for superiority testing an anti-obesity medication (SELECT) is underway with semaglutide 2.4 mg. A positive outcome will further promote the concept that weight management should be a primary target for cardiometabolic disease control. In phase 3, tirzepatide and cagrilintide/semaglutide combination are showing promise for even greater weight loss efficacy. Another recently approved medication takes a personalized medicine approach; setmelanotide is approved as a therapy for those with some of the ultra-rare genetic diseases characterized by severe, early onset obesity. This chapter reviews the currently available and anticipated medications for chronic weight management as well as those approved for the genetic and syndromic obesities.
    MeSH term(s) Anti-Obesity Agents/therapeutic use ; Humans ; Islet Amyloid Polypeptide ; Obesity/drug therapy ; Phentermine/therapeutic use ; Weight Loss
    Chemical Substances Anti-Obesity Agents ; Islet Amyloid Polypeptide ; cagrilintide (AO43BIF1U8) ; Phentermine (C045TQL4WP)
    Language English
    Publishing date 2021-11-12
    Publishing country Germany
    Document type Journal Article
    ISSN 0171-2004
    ISSN 0171-2004
    DOI 10.1007/164_2021_560
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Sign. bis Bd. 125 (1997): 1982 A 2146: Show issues
     danach: Sign. bei den Einzelbänden: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article ; Online: An Innovative Approach to Employer-Provided Benefits for Obesity Care: A Case Report on H-E-B's Healthier Lifestyle Choices Program.

    Ammerman, Abigail / Ryan, Donna H

    NAM perspectives

    2022  Volume 2022

    Language English
    Publishing date 2022-09-19
    Publishing country United States
    Document type Journal Article
    ISSN 2578-6865
    ISSN (online) 2578-6865
    DOI 10.31478/202209a
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  8. Article ; Online: Setmelanotide: what does it mean for clinical care of patients with obesity?

    Ryan, Donna H

    The lancet. Diabetes & endocrinology

    2020  Volume 8, Issue 12, Page(s) 933–935

    MeSH term(s) Humans ; Obesity ; Obesity, Morbid ; Pro-Opiomelanocortin ; Receptor, Melanocortin, Type 4 ; alpha-MSH/analogs & derivatives
    Chemical Substances MC4R protein, human ; Receptor, Melanocortin, Type 4 ; setmelanotide ; alpha-MSH (581-05-5) ; Pro-Opiomelanocortin (66796-54-1)
    Language English
    Publishing date 2020-10-30
    Publishing country England
    Document type Journal Article ; Comment
    ISSN 2213-8595
    ISSN (online) 2213-8595
    DOI 10.1016/S2213-8587(20)30366-1
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  9. Article ; Online: 2020: It Was Quite a Year!

    Ryan, Donna H / Ravussin, Eric

    Obesity (Silver Spring, Md.)

    2021  Volume 29, Issue 1, Page(s) 9–10

    Language English
    Publishing date 2021-09-07
    Publishing country United States
    Document type Editorial
    ZDB-ID 2230457-5
    ISSN 1930-739X ; 1071-7323 ; 1930-7381
    ISSN (online) 1930-739X
    ISSN 1071-7323 ; 1930-7381
    DOI 10.1002/oby.23092
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 4061: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MG 87: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article: Energy Balance and Weight Loss for Diabetes Remission.

    Ryan, Donna H

    Diabetes spectrum : a publication of the American Diabetes Association

    2020  Volume 33, Issue 2, Page(s) 117–124

    Abstract: Diabetes remission-the occurrence of durable normoglycemia without antidiabetic medications-has been demonstrated in some patients with type 2 diabetes who have achieved and sustained weight loss through lifestyle intervention or metabolic and bariatric ... ...

    Abstract Diabetes remission-the occurrence of durable normoglycemia without antidiabetic medications-has been demonstrated in some patients with type 2 diabetes who have achieved and sustained weight loss through lifestyle intervention or metabolic and bariatric surgery. Although this pursuit would represent a paradigm shift in our diabetes chronic care model, could diabetes remission become a routine treatment strategy in patients with type 2 diabetes? This article reviews the mechanisms by which weight loss can drive improvements in insulin sensitivity and β-cell function sufficient to normalize glycemia, treatment approaches that provide evidence for diabetes remission, and avenues for developing the research and discovery that will be required to make diabetes remission possible as part of the routine medical management of type 2 diabetes.
    Language English
    Publishing date 2020-05-18
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2211544-4
    ISSN 1040-9165
    ISSN 1040-9165
    DOI 10.2337/ds20-0005
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6232: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top